media – Page 550 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Can An mHealth Kit Improve Outcomes in Workers Comp Treatment?

Cedars-Sinai will be testing a digital pain-reduction kit, which includes VR glasses and mHealth wearables, to see if mobile health technology can replace opioids for people recovering from workplace injuries.
- Source: mHealth Intelligence
- 791
- March 12, 2018
digital health mHealth Researches
Science 37 and Novartis Sign Strategic Alliance to Advance Decentralized Clinical Trials

Science 37, a trailblazing company focused on “site-less” clinical trials, announced today a strategic alliance with Novartis that will support the development of its new decentralized clinical trial (DCT) offerings. This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services.
- Source: Science 37
- 572
- March 12, 2018
Company Insight digital health Novartis
Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

Pfizer Inc. announced a positive outcome from today’s U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting. The GIDAC met to discuss Pfizer’s supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), which is currently under review by the FDA, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
- Source: finance.yahoo
- 698
- March 12, 2018
FDA Pfizer UC XELJANZ
Merck and Eisai Ink $5.76B Cancer Deal

Merck & Company and Tokyo-based Eisai Inc. have signed a strategic collaboration deal to develop and commercialize Lenvima (lenvatinib mesylate) with Merck’s anti-PD-1 drug Keytruda (pembrolizumab).
- Source: Biospace
- 508
- March 12, 2018
keytruda LENVIMA Market Views
GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
- Source: us.gsk
- 884
- March 12, 2018
asthma EC GSK Relvar Ellipta
Sanofi, Evotec in major infectious disease R&D transfer and license deal

Big Pharma Sanofi and German CRO-biotech drug discovery hybrid Evotec are penning a deal that will see Sanofi license out a host of infectious disease assets to the biotech, with 100 staffers also moving into its R&D engine.
- Source: Fiercebiotech
- 543
- March 12, 2018
infections Market Views R&D
Health app adoption tripled since 2014, Accenture survey finds

Use of telemedicine has gone up as well, but not as dramatically, respondents say.
- Source: HealthcareITNews
- 984
- March 12, 2018
digital health Market Views mHealth
Five tips for exploring pharmaceutical drug export markets

For pharmaceutical companies who want to explore international markets, identifying these target markets is the first step. Being able to pinpoint the right target market, will increase the probability for more business deals. In order to help you with this process, we have listed 5 of the more important aspects to consider.
- Source: Ddu
- 809
- March 9, 2018
Ddu College pharmaceutical
Epigenetic Dysregulation May Be Key to Onset

Greater than 90% of all Alzheimer’s disease (AD) cases are sporadic, meaning there are few hereditary risk factors for developing the disease. Although certain genetic variants increase the risk of AD, age is the strongest known risk factor. Yet, understanding how the underlying molecular mechanisms of aging predispose individuals to AD has remained elusive. Now, a team of researchers from the Perelman School of Medicine at the University of Pennsylvania have discovered what they believe are changes to the normal epigenetic landscape that lead to the onset of Alzheimer’s.
- Source: Pixabay
- 588
- March 9, 2018
Alzheimer's Researches
GlaxoSmithKline’s Fluarix protects young children in large phase 3 test

GSK touted phase 3 data of its quadrivalent flu vaccine Fluarix Tetra. As a severe flu season continues to unfold in the U.S., GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who are among the most vulnerable to the virus.
- Source: Fiercepharma
- 753
- March 9, 2018
Clinical Trials flu vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.